Biomarker discovery
At the forefront of biosensor innovation, Aqsens Health collaborates with leading research institutions worldwide to accelerate breakthroughs in early disease detection and personalized treatment response monitoring. Aqsens’ unique Biomarker discovery process and tools provide researchers and biomedical companies access to cutting-edge phage-biosensor technology, enabling them to gain valuable insights, identify new biomarkers, and accelerate research towards transformative medical advancements.
AQ Lab for biomarker discovery process
AQ Lab is a purposely built web platform designed to perform the biomarker discovery process using both Aqsens Health’s chemical- and biosensors. It guides users through the discovery process from the development of biosensors to measurement protocols and quality controls, with integrated primary analysis tools.
AQ Lab enables research collaborators to perform high-quality research and biomarker discovery with full IPR protection, and supervision and guidance from Aqsens Health’s team.
Biomarker discovery case studies.
-
Aqsens Health is taking part in a cross-disciplinary Parkinson’s disease study in collaboration with Professor Valtteri Kaasinen from The Department of Clinical Neurosciences at the University of Turku. The aim of the study is to improve Parkinson’s disease’s diagnostic accuracy with a saliva-based test using Aqsens Health's biosensor technology.
Patient recruitment for the study began in early 2024.
-
A joint project between Aqsens Health and Medircortex Oy successfully demonstrated Aqsens’ biosensors capability to detect specific glycan structure caused by Traumatic Brain Injury (TBI) from saliva. By detecting specific glycan structures in saliva, previously very difficult with antibody approaches, this research opens new avenues for early and accurate TBI detection and illustrates the biosensors capability to detect glycan structures.
-
Aqsens Health Harvard Medical School lung transplantation team started a project to research organ transplantation rejection in patients using biosensors developed by Aqsens in late 2023. Through this project, Aqsens can further fine tune the biosensor’s capabilities in identifying regulators that control the human immune system activation in organ transplantation.
-
In 2023 Aqsens Health and research teams from the Shanghai Jiao Tong University (Shanghai Public Health Clinical Center and Shanghai Institute of Infectious Diseases) began a new joint project focusing on the detection of lung cancer and tuberculosis from saliva and other biological samples using Aqsens Health’s biosensors.
Project sample collection started in early 2024.
-
Aqsens Health’s proof-of-concept study aims to understand how biosensors can help in monitoring cancer treatment effectiveness and cancer recurrence. In this study urine samples were taken before the treatment, operation and during recovery with a diary of diet and exercise. All urine samples were fractionated and each molecule layer had its own biosensors, creating a unique fingerprint of the day in question.
The plan is to look at the changes as both individual signals as well as individualized fingerprints, and to find possible clinical correlations between the two.